Abstract
Effective efforts to screen for agents that protect against the devastating effects of stroke have not produced viable results thus far. As a result this article reviews the possible role of ethanol as a neuroprotective agent in stroke and traumatic brain injury (TBI). Previous studies have associated ethanol consumption with a decreased risk of ischemic stroke, suggesting a neuroprotective mechanism. The translation of this clinical knowledge into basic science research with the goal of new therapy for acute stroke patients remains in its initial stages. In a recent study involving rats, we have shown that ethanol administration, in the correct dose after stroke onset, protects against ischemia-induced brain injury. The purpose of this paper is to discuss ethanol’s neuroprotective properties in stroke when consumed as a preconditioning agent, in TBI with a positive blood alcohol content, and finally in stroke treatment, with the goal of using post-ischemia ethanol (PIE) therapy to ameliorate brain damage in the future.
Keywords: Ethanol, alcohol, stroke therapy, ischemia/reperfusion injury, traumatic brain injury therapy, neuroprotection
Current Drug Targets
Title:Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Volume: 14 Issue: 1
Author(s): Karam Asmaro, Paul Fu and Yuchuan Ding
Affiliation:
Keywords: Ethanol, alcohol, stroke therapy, ischemia/reperfusion injury, traumatic brain injury therapy, neuroprotection
Abstract: Effective efforts to screen for agents that protect against the devastating effects of stroke have not produced viable results thus far. As a result this article reviews the possible role of ethanol as a neuroprotective agent in stroke and traumatic brain injury (TBI). Previous studies have associated ethanol consumption with a decreased risk of ischemic stroke, suggesting a neuroprotective mechanism. The translation of this clinical knowledge into basic science research with the goal of new therapy for acute stroke patients remains in its initial stages. In a recent study involving rats, we have shown that ethanol administration, in the correct dose after stroke onset, protects against ischemia-induced brain injury. The purpose of this paper is to discuss ethanol’s neuroprotective properties in stroke when consumed as a preconditioning agent, in TBI with a positive blood alcohol content, and finally in stroke treatment, with the goal of using post-ischemia ethanol (PIE) therapy to ameliorate brain damage in the future.
Export Options
About this article
Cite this article as:
Asmaro Karam, Fu Paul and Ding Yuchuan, Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug, Current Drug Targets 2013; 14 (1) . https://dx.doi.org/10.2174/1389450111314010008
DOI https://dx.doi.org/10.2174/1389450111314010008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Diagnostic Biomarkers of Epilepsy
Current Pharmaceutical Biotechnology miR-15b Suppression of Bcl-2 Contributes to Cerebral Ischemic Injury and is Reversed by Sevoflurane Preconditioning
CNS & Neurological Disorders - Drug Targets The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Iontophoresis: Drug Delivery System by Applying an Electrical Potential Across the Skin
Drug Delivery Letters Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Recent Advances in the Design and Synthesis of Prednisolone and Methylprednisolone Conjugates
Current Pharmaceutical Design Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke
Current Medicinal Chemistry Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets In Utero Exposure to Phthalates and Fetal Development
Current Medicinal Chemistry Estrogen Receptors: Mechanism of Action and Relevance to Schizophrenia
Current Psychiatry Reviews Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology